ZLDPF Zealand Pharma A/S

OTC
$35.93

Zealand Pharma A/S (ZLDPF) is expected to report earnings on February 11, 2027, before the market open. The consensus earnings estimate is a loss of $1.85 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.2% since its last earnings release on November 12, 2026.

Zealand Pharma A/S Beat Consensus Estimates
Thursday, November 12, 2026 · 12:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · Before Open
Earnings Whisper
-
vs ($1.85)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $35.62

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company's pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.